HOME › Press Releases › Sunitinib Malate Market worth 76.7 Million USD by 2021
Sunitinib Malate Market worth 76.7 Million USD by 2021
The report "Sunitinib Malate Market Forecast for Pancreatic Cancer, 2016-2017, G7 Countries, (U.S., Germany, France, U.K., Italy, Spain, Japan)", The sunitinib malate market for pancreatic cancer is projected to reach USD 76.7 Million by 2021, at a CAGR of 13.9% from 2016 to 2021.
Browse 14 market data Tables spread through 26 Pages and in-depth TOC on "Sunitinib Malate Market Forecast for Pancreatic Cancer, 2016-2017, G7 Countries, (U.S., Germany, France, U.K., Italy, Spain, Japan)"
Early buyers will receive 10% customization on reports.
A number of factors, such as increasing incidence of pancreatic cancer, availability of a limited number of drug therapeutic options for the treatment of advanced pancreatic neuroendocrine tumors, and poor diagnosis rate in the early stages of pancreatic cancer are driving the demand of sunitinib malate in the treatment of pancreatic cancer. Also, the overall number of patients who are eligible for taking sunitinib malate is expected to grow at a high CAGR during the forecast period.
In this report, the market is segmented into seven country-level segments, namely, the U.S., Germany, France, the U.K., Italy, Spain, and Japan. The U.S. is expected to dominate this market primarily due to the higher number of patients suffering from pancreatic cancer in the country. However, the market in the U.K. is expected to witness the highest growth rate during the forecast period.
This report contains detailed analysis of the sunitinib malate market for pancreatic cancer in terms of epidemiology, number of drug-treated patients suffering from pancreatic neuroendocrine tumors (pNET), percentage of patients eligible for taking sunitinib malate, penetration of sunitinib malate in pNET patients, number of pancreatic cancer patients, incidence rate of pancreatic cancer, 5-year survival rate of pNET patients, penetration of drug therapy in pancreatic cancer treatment, and trends in the adoption of sunitinib malate. This report also includes pricing analysis of sunitinib malate in all G7 countries and year-on-year market size of sunitinib malate for pancreatic cancer from 2010 to 2021.
MarketsandMarkets is the world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India